Table 2.
Participants characteristics in each injecting-related cohort, 2010–June 2021
| Co-variates | Injecting-related cohort | ||
|---|---|---|---|
| Needle exchange surveillance initiative cohort (NESI)a (% of N) | Opiate agonist therapy (OAT) cohort (% of N) | Injecting-related hospital admission (IRHA) cohort (% of N) | |
| Total, N | 6,110 | 14,257 | 12,621 |
| Time periodb | |||
| Pre-outbreak (2010–2014) | 3,302 (54%) | 11,908 (84%) | 4,826 (38%) |
| Early outbreak (2015–2016) | 940 (15%) | 9,519 (67%) | 3,347 (27%) |
| Ongoing outbreak (2017–2019) | 1,868 (31%) | 9,412 (66%) | 5,297 (42%) |
| COVID-19 (2020–June 2021) | – | 7,599 (53%) | 3,008 (24%) |
| Local authority area | |||
| Glasgow city | 4,586 (75%) | 10,466 (73%) | 8,178 (65%) |
| Rest of Glasgow | 1,524 (25%) | 3,791 (27%) | 4,443 (35%) |
| Not recorded/unknown | 0 | 0 | 0 |
| Gender | |||
| Male | 4,465 (73%) | 9,826 (69%) | 8,942 (71%) |
| Female | 1,618 (26%) | 4,431 (31%) | 3,679 (29%) |
| Not recorded/unknown | 27 (1%) | 0 | 0 |
| Age group, pre-outbreak (2010–2014) | |||
| < 35 | 1,385 (42%) | 3,170 (27%) | 2,079 (43%) |
| 35–45 | 1,613 (49%) | 5,661 (47%) | 1,705 (35%) |
| 46 + | 301 (9%) | 3,077 (26%) | 1,042 (22%) |
| Not recorded/unknown | 3 (< 1%) | 0 | 0 |
| Age group, early outbreak (2015–2016) | |||
| < 35 | 273 (29%) | 1,667 (18%) | 1,190 (36%) |
| 35–45 | 479 (51%) | 4,588 (48%) | 1,179 (35%) |
| 46 + | 188 (20%) | 3,264 (34%) | 978 (29%) |
| Not recorded/unknown | 0 | 0 | 0 |
| Age group, ongoing outbreak (2017–2019) | |||
| < 35 | 297 (16%) | 1,146 (12%) | 1,784 (34%) |
| 35–45 | 1,024 (55%) | 3,939 (42%) | 1,703 (32%) |
| 46 + | 544 (29%) | 4,327 (46%) | 1,810 (34%) |
| Not recorded/unknown | 3 (< 1%) | 0 | 0 |
| Age group, COVID-19 (2020–2021) | |||
| < 35 | – | 755 (10%) | 911 (30%) |
| 35–45 | – | 2,893 (38%) | 950 (32%) |
| 46 + | – | 3,951 (52%) | 1,147 (38%) |
| Not recorded/unknown | – | 0 | 0 |
| Prescribed OATc,d | |||
| Not recorded/unknown | |||
| Not prescribed OAT | 426 (7%) | – | 6,552 (52%) |
| In the last 6 months | 5,039 (82%) | 14,527 (100%)e | 5,064 (40%) |
| In the past but not the last 6 months | 607 (10%) | – | 1,005 (8%) |
| Not recorded/unknown | 38 (1%) | – | 0 |
| Injecting-related hospital admission in the last 2 yearsd | |||
| Yes | – | 3,187 (22%) | 12,621 (100%)e |
| No | – | 11,070 (78%)e | – |
| Not recorded/unknown | – | 0 | – |
NESI Needle Exchange Surveillance Initiative, OAT Opioid agonist therapy, IRHA Injecting-related hospital admission
aNESI cohort is described by participations in the NESI survey
bRelates to recruitment period for NESI cohort; Time-varying co-variate for OAT and IRHA, people can be included in multiple time periods
cNESI cohort: prescribed methadone
dOAT cohort, relative to last OAT prescription date; IRHA cohort: relative to date of last hospital admission
eDefinition of cohort (OAT prescription or IRHA) translates to 100% for these categories